Menu
Search
|

Menu

Close
X

Zoetis Inc ZTS.N (New York Stock Exchange)

82.79 USD
+2.03 (+2.51%)
As of Feb 24
chart
Previous Close 80.76
Open 81.17
Volume 596,669
3m Avg Volume 701,244
Today’s High 82.93
Today’s Low 81.04
52 Week High 82.93
52 Week Low 52.25
Shares Outstanding (mil) 489.11
Market Capitalization (mil) 31,180.87
Forward P/E 36.00
Dividend (Yield %) 0.10 ( 0.66 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 21 analysts

KEY STATS

Revenue (mm, USD)
FY17
5,307
FY16
4,888
FY15
4,765
EPS (USD)
FY17
2.183
FY16
1.648
FY15
0.675
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
36.00
32.90
Price to Sales (TTM)
vs sector
6.21
5.77
Price to Book (MRQ)
vs sector
18.20
5.41
Price to Cash Flow (TTM)
vs sector
27.82
23.42
Total Debt to Equity (MRQ)
vs sector
266.41
16.52
LT Debt to Equity (MRQ)
vs sector
216.85
12.22
Return on Investment (TTM)
vs sector
14.09
14.43
Return on Equity (TTM)
vs sector
57.16
16.13

EXECUTIVE LEADERSHIP

Michael McCallister
Non-Executive Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Juan Alaix
Chief Executive Officer, Director, Since 2012
Salary: $1,150,000.00
Bonus: --
Glenn David
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $483,030.00
Bonus: --
Roxanne Lagano
Chief Human Resource Officer, Executive Vice President, Since 2012
Salary: --
Bonus: --
Andrew Fenton
Executive Vice President, Chief Information Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

10 Sylvan Way
PARSIPPANY   NJ   07054-3825

Phone: +1973.8227000

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

SPONSORED STORIES